Bile duct carcinoma
MONDO:0005496A carcinoma that arises from epithelial cells of the bile duct
Also known as: bile duct cancer, bile duct cancer (including cholangiocarcinoma), bile duct carcinoma, carcinoma of bile duct
3350 clinical trials for this condition and its sub-types, 20 tagged with Bile duct carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bile duct carcinoma
-
Extrahepatic bile duct carcinoma 51 trials · 432 incl. sub-types
6 sub-types
- Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types Sub-types →
- Carcinoma of the ampulla of vater 29 trials · 65 incl. sub-types Sub-types →
- Distal biliary tract carcinoma 32 trials
- Carcinoma in situ of extrahepatic bile duct 0 trials
- Extrahepatic bile duct leiomyosarcoma 0 trials
- Extrahepatic bile duct squamous cell carcinoma 0 trials Sub-types →
-
Bile duct adenocarcinoma 17 trials · 419 incl. sub-types
1 sub-type
- Extrahepatic bile duct adenocarcinoma 2 trials · 409 incl. sub-types Sub-types →
-
Bile duct carcinoma in situ 0 trials
1 sub-type
-
Squamous cell bile duct carcinoma 0 trials
2 sub-types
Most studied deeper sub-types
-
Can adding immunotherapy to standard cancer care be safe for indian patients?
Disease control Not yet recruitingThis trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…
Phase 4 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can matching drugs to tumor genes beat biliary cancer?
Disease control Not yet recruitingThis umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims …
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control Not yet recruitingThis study tests a combination of two drugs (vebecotototo and putli monoclonal antibodies) in 44 people with advanced bile duct cancer that has a specific marker (EGFR) and has not responded to prior treatment. The goal is to see if the combination can shrink tumors and control t…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC